Kunming Biomed International provides NHP disease models for pharmacological studies for all kind of metabolic diseases, but also for NCS related diseases as well as eye diseases and immune & inflammatory diseases. Funded in the year 2006, KBI got its full AAALAC accreditation in 2011 and kicked-off its CRO business in 2013. Since then KBI continues its successful development, based on many years of metabolic research and support with related co-morbidities as NASH, Cardiovascular and Kidney Diseases. With TriApex group joining in 2021, KBI offers a comprehensive service from early target engagement pharmacology studies, biomarker analysis, histo-pathology until pharmacokinetic, toxicology studies, drug ADMEs, and bioanalytical tests. KBI developed throughout the years a worldwide network to most of pharmaceutical and biotech companies, referencing for excellent scientific and service related support, improving the success rate and closing the gap between pre-clinical and clinical research.